ALK and non-small cell lung carcinoma: Quite recently, the FDA and/or EMA approved therapeutics for MET-Exon-14 skipping alterations in NSCLC, and crizotinib [48,49], a tyrosine kinase inhibitor (TKI) targeting ALK, MET and ROS is under clinical development with inclusion criteria of MET-mutations.